Cognitive impairment and medication adherence post-stroke: A five-year follow-up of the ASPIRE-S cohort


Autoři: Daniela Rohde aff001;  Eva Gaynor aff002;  Margaret Large aff003;  Lisa Mellon aff001;  Kathleen Bennett aff001;  David J. Williams aff004;  Linda Brewer aff004;  Patricia Hall aff003;  Elizabeth Callaly aff005;  Eamon Dolan aff006;  Anne Hickey aff001
Působiště autorů: Division of Population Health Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland aff001;  Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland aff002;  Clinical Research Centre, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland aff003;  Geriatric and Stroke Medicine, Royal College of Surgeons in Ireland and Beaumont Hospital, Dublin, Ireland aff004;  Geriatric Medicine, Mater Misericordiae University Hospital, Dublin, Ireland aff005;  Geriatric Medicine, Connolly Hospital, Dublin, Ireland aff006
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0223997

Souhrn

Background

Control of vascular risk factors is essential for secondary stroke prevention. However, adherence to secondary prevention medications is often suboptimal, and may be affected by cognitive impairment. Few studies to date have examined associations between cognitive impairment and medication adherence post-stroke, and none have considered whether adherence to secondary prevention medications might affect subsequent cognitive function. The aim of this study was to explore prospective associations between cognitive impairment and medication non-adherence post-stroke.

Methods

A five-year follow-up of 108 stroke survivors from the Action on Secondary Prevention Interventions and Rehabilitation in Stroke (ASPIRE-S) prospective observational cohort study. Cognitive function was assessed using the Montreal Cognitive Assessment at 6 months, and a neuropsychological test battery at 5 years. Adherence to antihypertensive, antithrombotic and lipid-lowering medications was assessed using prescription refill data.

Results

The prevalence of cognitive impairment at five years was 35.6%. The prevalence of non-adherence ranged from 15.1% for lipid-lowering agents to 30.2% for antithrombotics. There were no statistically significant associations between medication non-adherence in the first year post-stroke and cognitive impairment at 5 years, nor between cognitive impairment at 6 months and non-adherence at 5 years. Stroke survivors with cognitive impairment were significantly more likely to report receiving help with taking medications [OR (95% CI): 4.84 (1.17, 20.07)].

Conclusions

This is the first study to explore the potential impact of non-adherence to secondary prevention medications on cognitive impairment in stroke survivors. Findings highlight the role of family members and caregivers in assisting stroke survivors with medication administration, particularly in the context of deficits in cognitive function. Involving family members and caregivers may be a legitimate and cost-effective strategy to improve medication adherence in stroke survivors.

Klíčová slova:

Antihypertensives – Cardiology – Cognitive impairment – Lipids – Medical risk factors – Medicine and health sciences – Neuropsychological testing – Stroke


Zdroje

1. Brainin M, Tuomilehto J, Heiss WD, Bornstein NM, Bath PM, Teuschl Y, et al. Post-stroke cognitive decline: an update and perspectives for clinical research. Eur J Neurol. 2015;22(2):229–38, e13-6. Epub 2014/12/11. doi: 10.1111/ene.12626 25492161.

2. Atteih S, Mellon L, Hall P, Brewer L, Horgan F, Williams D, et al. Implications of stroke for caregiver outcomes: findings from the ASPIRE-S study. International journal of stroke: official journal of the International Stroke Society. 2015;10(6):918–23. Epub 2015/06/11. doi: 10.1111/ijs.12535 26061711.

3. Black CM, Ritchie CW, Khandker RK, Wood R, Jones E, Hu X, et al. Non-professional caregiver burden is associated with the severity of patients' cognitive impairment. PloS one. 2018;13(12):e0204110. Epub 2018/12/07. doi: 10.1371/journal.pone.0204110 30521532; PubMed Central PMCID: PMC6283568 following competing interests. Christopher M. Black, Rezaul K. Khandker, Xiaohan Hu, Baishali M. Ambegaonkar, are all current or previous employees of Merck & Co who funded the research. Robert Wood and Eddie Jones are employees of Adelphi Real World which was paid by Merck for conducting the research. Craig W. Ritchie, received consultancy fees from Merck. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

4. Blomgren C, Samuelsson H, Blomstrand C, Jern C, Jood K, Claesson L. Long-term performance of instrumental activities of daily living in young and middle-aged stroke survivors-Impact of cognitive dysfunction, emotional problems and fatigue. PloS one. 2019;14(5):e0216822. Epub 2019/05/17. doi: 10.1371/journal.pone.0216822 31095631.

5. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. The Lancet Neurology. 2009;8(11):1006–18. Epub 2009/09/29. doi: 10.1016/S1474-4422(09)70236-4 19782001.

6. Sexton E, McLoughlin A, Merriman NA, Donnelly NA, Rohde D, Wren M-A, et al. Systematic review and meta-analysis of the prevelance of Cognitive Impairment No Dementia (CIND) in the first year post-stroke. European Stroke Journal. 2019. doi: 10.1177/2396987318825484 31259264

7. Institute of Medicine. Cognitive aging: Progress in understanding and opportunities for action. Washington DC: The National Academies Press, 2015.

8. Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vascular health and risk management. 2010;6:775–85. Epub 2010/09/23. doi: 10.2147/vhrm.s7343 20859546; PubMed Central PMCID: PMC2941788.

9. Rohde D, Gaynor E, Large M, Mellon L, Hall P, Brewer L, et al. The impact of cognitive impairment on poststroke outcomes: A 5-year follow-up. Journal of geriatric psychiatry and neurology. 2019. doi: 10.1177/0891988719853044 31167593

10. Unverzagt FW, McClure LA, Wadley VG, Jenny NS, Go RC, Cushman M, et al. Vascular risk factors and cognitive impairment in a stroke-free cohort. Neurology. 2011;77(19):1729–36. Epub 2011/11/10. doi: 10.1212/WNL.0b013e318236ef23 22067959; PubMed Central PMCID: PMC3208949.

11. Peng M, Chen G, Tang KL, Quan H, Smith EE, Faris P, et al. Blood pressure at age 60–65 versus age 70–75 and vascular dementia: a population based observational study. BMC Geriatr. 2017;17(1):252. Epub 2017/10/29. doi: 10.1186/s12877-017-0649-3 29078750; PubMed Central PMCID: PMC5658926.

12. Douiri A, McKevitt C, Emmett ES, Rudd AG, Wolfe CD. Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation. 2013;128(12):1341–8. Epub 2013/08/13. doi: 10.1161/CIRCULATIONAHA.113.002236 23935013.

13. Al AlShaikh S, Quinn T, Dunn W, Walters M, Dawson J. Predictive factors of non-adherence to secondary preventative medication after stroke or transient ischaemic attack: A systematic review and meta-analyses. European Stroke Journal. 2016;1(2):65–75. doi: 10.1177/2396987316647187 29900404

14. Rohde D, Merriman NA, Doyle F, Bennett K, Williams D, Hickey A. Does cognitive impairment impact adherence? A systematic review and meta-analysis of the association between cognitive impairment and medication non-adherence in stroke. PloS one. 2017;12(12):e0189339. Epub 2017/12/09. doi: 10.1371/journal.pone.0189339 29220386; PubMed Central PMCID: PMC5722379.

15. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. British journal of clinical pharmacology. 2012;73(5):691–705. Epub 2012/04/11. doi: 10.1111/j.1365-2125.2012.04167.x 22486599; PubMed Central PMCID: PMC3403197.

16. Kronish IM, Ye S. Adherence to cardiovascular medications: lessons learned and future directions. Prog Cardiovasc Dis. 2013;55(6):590–600. Epub 2013/04/30. doi: 10.1016/j.pcad.2013.02.001 23621969; PubMed Central PMCID: PMC3639439.

17. Brewer L, Mellon L, Hall P, Dolan E, Horgan F, Shelley E, et al. Secondary prevention after ischaemic stroke: the ASPIRE-S study. BMC neurology. 2015;15:216. Epub 2015/10/27. doi: 10.1186/s12883-015-0466-2 26492943; PubMed Central PMCID: PMC4619229.

18. Mellon L, Brewer L, Hall P, Horgan F, Williams D, Hickey A, et al. Cognitive impairment six months after ischaemic stroke: A profile from the ASPIRE-S study. BMC Neurology. 2015;15(31).

19. Rohde D, Williams D, Gaynor E, Bennett K, Dolan E, Callaly E, et al. Secondary prevention and cognitive function after stroke: a study protocol for a 5-year follow-up of the ASPIRE-S cohort. BMJ open. 2017;7(3):e014819. Epub 2017/03/30. doi: 10.1136/bmjopen-2016-014819 28348196.

20. Gaynor E, Rohde D, Large M, Mellon L, Hall P, Brewer L, et al. Cognitive Impairment, Vulnerability, and Mortality Post Ischemic Stroke: A Five-Year Follow-Up of the Action on Secondary Prevention Interventions and Rehabilitation in Stroke (ASPIRE-S) Cohort. Journal of Stroke and Cerebrovascular Diseases. 2018;27(9):2466–73. doi: 10.1016/j.jstrokecerebrovasdis.2018.05.002 29803601

21. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9. Epub 2005/04/09. doi: 10.1111/j.1532-5415.2005.53221.x 15817019.

22. Waldron-Perrine B, Axelrod BN. Determining an appropriate cutting score for indication of impairment on the Montreal Cognitive Assessment. Int J Geriatr Psychiatry. 2012;27(11):1189–94. Epub 2012/01/10. doi: 10.1002/gps.3768 22228412.

23. Coen RF, Cahill R, Lawlor BA. Things to watch out for when using the Montreal cognitive assessment (MoCA). Int J Geriatr Psychiatry. 2011;26(1):107–8. Epub 2010/12/16. doi: 10.1002/gps.2471 21157857.

24. Luis CA, Keegan AP, Mullan M. Cross validation of the Montreal Cognitive Assessment in community dwelling older adults residing in the Southeastern US. Int J Geriatr Psychiatry. 2009;24(2):197–202. doi: 10.1002/gps.2101 18850670

25. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37(9):2220–41. Epub 2006/08/19. doi: 10.1161/01.STR.0000237236.88823.47 16917086.

26. Wechsler D. Wechsler Adult Intelligence Scale (WAIS-III). 3rd ed. San Antonio, TX:: Harcourt Assessment; 1997.

27. Delis DC, Kaplan E, Kramer JH. The Delis- Kaplan Executive Function System. San Antonio: The Psychological Corporation; 2001.

28. Brandt J. The hopkins verbal learning test: Development of a new memory test with six equivalent forms. Clinical Neuropsychologist. 1991;5(2):125–42. doi: 10.1080/13854049108403297

29. Reitan RM. Validity of the Trail Making Test as an Indicator of Organic Brain Damage. Perceptual and Motor Skills. 1958;8(3):271–6. doi: 10.2466/pms.1958.8.3.271

30. Hester RL, Kinsella GJ, Ong B, Turner M. Hopkins Verbal Learning Test: Normative data for older Australian adults. Australian Psychologist. 2004;39(3):251–5.

31. Nakling AE, Aarsland D, Næss H, Wollschlaeger D, Fladby T, Hofstad H, et al. Cognitive Deficits in Chronic Stroke Patients: Neuropsychological Assessment, Depression, and Self-Reports. Dementia and Geriatric Cognitive Disorders Extra. 2017;7(2):283–96. doi: 10.1159/000478851 29033974

32. Harrison JE, Lophaven S, Olsen CK. Which Cognitive Domains are Improved by Treatment with Vortioxetine? The international journal of neuropsychopharmacology. 2016;19(10):pyw054. Epub 2016/05/28. doi: 10.1093/ijnp/pyw054 27231256; PubMed Central PMCID: PMC5091828.

33. Pendlebury ST, Mariz J, Bull L, Mehta Z, Rothwell PM. MoCA, ACE-R, and MMSE versus the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards Neuropsychological Battery after TIA and stroke. Stroke. 2012;43(2):464–9. Epub 2011/12/14. doi: 10.1161/STROKEAHA.111.633586 22156700.

34. Barbay M, Taillia H, Nedelec-Ciceri C, Bompaire F, Bonnin C, Varvat J, et al. Prevalence of Poststroke Neurocognitive Disorders Using National Institute of Neurological Disorders and Stroke-Canadian Stroke Network, VASCOG Criteria (Vascular Behavioral and Cognitive Disorders), and Optimized Criteria of Cognitive Deficit. Stroke. 2018;49(5):1141–7. Epub 2018/04/13. doi: 10.1161/STROKEAHA.117.018889 29643258.

35. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychology & health. 1999;14(1):1–24. doi: 10.1080/08870449908407311

36. Lee CS, Tan JHM, Sankari U, Koh YLE, Tan NC. Assessing oral medication adherence among patients with type 2 diabetes mellitus treated with polytherapy in a developed Asian community: a cross-sectional study. BMJ open. 2017;7(9):e016317. Epub 2017/09/16. doi: 10.1136/bmjopen-2017-016317 28912194; PubMed Central PMCID: PMC5640112.

37. Brewer L. Profile of cardiovascular risk factors at six months post ischaemic stroke in Dublin: the ASPIRE-S study. Dublin, Ireland: Royal College of Surgeons in Ireland; 2014.

38. Sinnott SJ, Bennett K, Cahir C. Pharmacoepidemiology resources in Ireland-an introduction to pharmacy claims data. Eur J Clin Pharmacol. 2017;73(11):1449–55. Epub 2017/08/19. doi: 10.1007/s00228-017-2310-7 28819675; PubMed Central PMCID: PMC5662670.

39. Rohde D, Hickey A, Williams D, Bennett K. Cognitive impairment and cardiovascular medication use: Results from wave 1 of The Irish Longitudinal Study on Ageing. Cardiovascular therapeutics. 2017;35(6). Epub 2017/08/25. doi: 10.1111/1755-5922.12300 28836733.

40. Al AlShaikh S, Quinn T, Dunn W, Walters M, Dawson J. Multimodal Interventions to Enhance Adherence to Secondary Preventive Medication after Stroke: A Systematic Review and Meta-Analyses. Cardiovascular therapeutics. 2016;34(2):85–93. Epub 2016/01/29. doi: 10.1111/1755-5922.12176 26820710.

41. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–35. Epub 2009/06/17. doi: 10.1161/CIRCULATIONAHA.108.768986 19528344.

42. Lindenstrøm E, Boysen G, Waage CL, à Rogvi Hansen B, Würtzen Nielsen P. Reliability of Scandinavian Neurological Stroke Scale. Cerebrovascular diseases (Basel, Switzerland). 1991;1(2):103–7. doi: 10.1159/000108825

43. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41. doi: 10.1161/01.str.24.1.35 7678184

44. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet (London, England). 1991;337(8756):1521–6. Epub 1991/06/22. doi: 10.1016/0140-6736(91)93206-o 1675378.

45. Bonita R, Beaglehole R. Recovery of motor function after stroke. Stroke. 1988;19(12):1497–500. Epub 1988/12/01. doi: 10.1161/01.str.19.12.1497 3201508.

46. Narasimhalu K, Ang S, De Silva DA, Wong MC, Chang HM, Chia KS, et al. The prognostic effects of poststroke cognitive impairment no dementia and domain-specific cognitive impairments in nondisabled ischemic stroke patients. Stroke. 2011;42(4):883–8. Epub 2011/02/19. doi: 10.1161/STROKEAHA.110.594671 21330625.

47. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Appl Psychol Meas. 1977;1(3):385–401.

48. Enderby PM, Wood VA, Wade DT, Hewer RL. The Frenchay Aphasia Screening Test: a short, simple test for aphasia appropriate for non-specialists. International rehabilitation medicine. 1987;8(4):166–70. Epub 1987/01/01. 2440825.

49. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European heart journal. 2016;37(29):2315–81. Epub 2016/05/26. doi: 10.1093/eurheartj/ehw106 27222591; PubMed Central PMCID: PMC4986030.

50. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (London, England). 1996;348(9038):1329–39. Epub 1996/11/16. doi: 10.1016/s0140-6736(96)09457-3 8918275.

51. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of the neurological sciences. 1996;143(1–2):1–13. Epub 1996/11/01. doi: 10.1016/s0022-510x(96)00308-5 8981292.

52. Weimar C, Diener HC, Alberts MJ, Steg PG, Bhatt DL, Wilson PW, et al. The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry. Stroke. 2009;40(2):350–4. Epub 2008/11/22. doi: 10.1161/STROKEAHA.108.521419 19023098.

53. Medical Research Council. MRC Ethics Guide 2007: Medical research involving adults who cannot consent. London: Medical Research Council, 2007.

54. Health Service Executive National Consent Advisory Group. National Consent Policy. Dublin: Health Service Executive; 2013 [accessed 15th March 2016]. Available from: http://www.hse.ie/eng/about/Who/qualityandpatientsafety/National_Consent_Policy/National%20Consent%20PolicyMay14.pdf.

55. Lim JS, Oh MS, Lee JH, Jung S, Kim C, Jang MU, et al. Prediction of post-stroke dementia using NINDS-CSN 5-minute neuropsychology protocol in acute stroke. International psychogeriatrics. 2017;29(5):777–84. Epub 2017/01/26. doi: 10.1017/S1041610216002520 28120733.

56. StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP., 2013.

57. Jamison J, Ayerbe L, Di Tanna GL, Sutton S, Mant J, De Simoni A. Evaluating practical support stroke survivors get with medicines and unmet needs in primary care: a survey. BMJ open. 2018;8(3):e019874. Epub 2018/03/13. doi: 10.1136/bmjopen-2017-019874 29526835; PubMed Central PMCID: PMC5855212.

58. Smith D, Lovell J, Weller C, Kennedy B, Winbolt M, Young C, et al. A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PloS one. 2017;12(2):e0170651. Epub 2017/02/07. doi: 10.1371/journal.pone.0170651 28166234; PubMed Central PMCID: PMC5293218.

59. Aston L, Hilton A, Moutela T, Shaw R, Maidment I. Exploring the evidence base for how people with dementia and their informal carers manage their medication in the community: a mixed studies review. BMC Geriatr. 2017;17(1):242. Epub 2017/10/20. doi: 10.1186/s12877-017-0638-6 29047339; PubMed Central PMCID: PMC5648510.

60. Mahon S, Parmar P, Barker-Collo S, Krishnamurthi R, Jones K, Theadom A, et al. Determinants, Prevalence, and Trajectory of Long-Term Post-Stroke Cognitive Impairment: Results from a 4-Year Follow-Up of the ARCOS-IV Study. Neuroepidemiology. 2017;49(3–4):129–34. doi: 10.1159/000484606 29145207

61. Delavaran H, Jönsson AC, Lövkvist H, Iwarsson S, Elmståhl S, Norrving B, et al. Cognitive function in stroke survivors: A 10-year follow-up study. Acta Neurologica Scandinavica. 2017;136(3):187–94. doi: 10.1111/ane.12709 27804110

62. Wessol JL, Russell CL, Cheng AL. A Systematic Review of Randomized Controlled Trials of Medication Adherence Interventions in Adult Stroke Survivors. The Journal of neuroscience nursing: journal of the American Association of Neuroscience Nurses. 2017;49(2):120–33. Epub 2017/02/25. doi: 10.1097/jnn.0000000000000266 28234660.

63. Lin CY, Ou HT, Nikoobakht M, Brostrom A, Arestedt K, Pakpour AH. Validation of the 5-Item Medication Adherence Report Scale in Older Stroke Patients in Iran. J Cardiovasc Nurs. 2018;33(6):536–43. Epub 2018/04/13. doi: 10.1097/JCN.0000000000000488 29649015.

64. El-Saifi N, Moyle W, Jones C, Alston-Knox C. Determinants of medication adherence in older people with dementia from the caregivers’ perspective. International psychogeriatrics. 2019;31(3):331–9. Epub 2018/05/11. doi: 10.1017/S1041610218000583 29747719

65. Wolfe CD, Crichton SL, Heuschmann PU, McKevitt CJ, Toschke AM, Grieve AP, et al. Estimates of outcomes up to ten years after stroke: analysis from the prospective South London Stroke Register. PLoS medicine. 2011;8(5):e1001033. Epub 2011/05/26. doi: 10.1371/journal.pmed.1001033 21610863; PubMed Central PMCID: PMC3096613.


Článek vyšel v časopise

PLOS One


2019 Číslo 10